Skip links

Improving The Drug Development Success Rate Through Knowledge-Empowered Modeling & Simulations.

Knowledge-Empowered Modeling & Simulation

Our modeling is driven by a deep understanding of biological systems, enabling us to provide knowledge-based insights for strategic decision-making and improving the success rate of drug development.

Proprietary data pool and AI/ML-analytics

Our extensive and exclusive data pool, coupled with cutting-edge AI/ML analytics, empowers us to extract valuable patterns and optimize drug development.

Our Core Team

Kas, PhD, has more than 25 years of experience in applying modeling to drug discovery and development across a broad range of therapeutic areas and treatment modalities. Kas has over 20 years of executive-level experience and led modeling teams at Applied Biomath LLC, Syngene International, and was the CSO of Strand Life Sciences Pvt. Ltd, headed up the Collaborative & D group for immunology products at Entelos and helped found a group to perform research in synthetic and hybrid vectors for gene delivery at Genetic Therapy Inc (Novartis). He has a PhD in Biomedical Engineering from Johns Hopkins University.
Kas Subramanian

CEO

Atefeh Kazeroonian, PhD, has over 10 years of experience in computational modelling and ML with a focus on immunology. She successfully led international projects in Computational Biology and Immunology and is a former PI of the Technical University of Munich (TUM). She has a PhD in applied mathematics from the Helmholtz Center in Munich and Technical University of Munich and published in multiple top-tier publications such as Nat. Immuno. PNAS, Bioinformatics, etc.
Atefeh Kazeroonian

Mechanistic Modeling VP

18+ years’ experience in clinical pharmacology, toxicology, pharmacometrics, and clinical trials. 15 years of experience consulting in clinical pharmacology & modeling/simulation. Former Vice President Clinical Pharmacology, Allucent. 15+ years in academic institutions, including 8 years leading a Clinical Trial Office; 5 years directing a Clinical Research Centre. PhD in Paediatric Clinical Pharmacology, the University of Otago, Dunedin School of Medicine, New Zealand and MPharm in Clinical Toxicology, the University of Florida. American Board of Clinical Pharmacology board certification, Fellow of the American College of Clinical Pharmacology and Certified Principal Investigator (CPI) Association of Clinical Research Professionals (ACRP)
Catherine Sherwin

Clinical Pharmacology & Pharmacometrics VP

Chris Reinert, MBA, SHRM-SCP, IFC-ACC, has over 14 years of experience in HR, talent acquisition, leadership development, and operations focusing on the biopharmaceutical industry across APAC, Europe and the USA. He built and led teams in Germany, UK, Australia, and China. He is focused on the Biomedical AI industry and building teams that harness the power of AI/ML and advanced modeling to enable biopharmaceutical companies to increase the efficiency of drug development.
Chris Reinert

COO

17+ years of industry experience in mechanistic modelling supporting drug discovery and development programs and drug-induced toxicity. Led the development of a precision-based predictive mechanistic platform for chemotherapy-induced cardiotoxicity in cancer patients; led the development of QSP models in the immunology discovery program. Key contributor in virtual liver project, and Co-inventor in the US patent for developing a methodology for predicting organ toxicity using system models. Authored multiple publications, posters, and book chapters on the application of mechanistic models and AI/ML techniques. Postgraduate in Life Sciences. Postgraduate Diploma Bioinformatics. PhD Mechanistic Modeling (NASH), expected 2024/25.
Rajeev Kumar

Mechanistic Modeling Senior Director

Over 7 years of Pharmacometrics experience. Worked on dosing regimen optimization in young malnourished children, developed PKPD models to predict drug efficacy, and disease models to aid in informing future trial designs. Postdoctoral fellow at Genentech and UCSF. PharmD-PhD specialized in pharmacometrics with experience in development of (semi-) mechanistic models in a Bayesian framework and clinical pharmacology PKPD/disease modeling, focused on the development of PBPK and multi-state models to assess compound toxicity.
Ségolène Siméon

Pharmacometrics Senior Scientist

Simon Junankar, PhD, has over 20 years of research experience in oncology and immuno-oncology. His research has made important discoveries in cancer biology, cancer inflammation, cancer cachexia, and the immune phenotype of breast cancer. He has many, highly cited publications in journals such as Cancer Discovery, Cancer Cell, Nature Medicine, Nature Genetics, Science, and Nature Communications.
Simon Junankar

Scientific Affairs Director

Our Scientific Advisory Board

Our Scientific Advisory Board plays a pivotal role in shaping our strategic decision, ensuring that we offer our clients science-driven excellence, scientific rigor, innovation, and that we stay at the forefront of advancements.

Professor Turtle is a hemato-oncologist and physician-scientist with expertise in genetically modified T cell immunotherapies for cancer. He completed a PhD at the University of Queensland then spent 17 years at Fred Hutchinson Cancer Center in Seattle, USA, where he was Professor and Anderson Family Endowed Chair for Immunotherapy. In 2022, he was appointed Professor and CLEARbridge Chair in Cancer Immunotherapy in the Faculty of Medicine and Health at the University of Sydney. He is a clinical academic at Royal North Shore Hospital in Sydney. His research laboratory focuses on understanding the factors governing the therapeutic immune response to cancer and the development of novel immunotherapies.
Professor Cameron Turtle

Scientific Advisor Immuno & Cell-Therapy

Professor Jason Roberts is Director of the University of Queensland Centre for Clinical Research (UQCCR) and an Australian National Health and Medical Research Council Leadership Fellow at The University of Queensland. He is a Clinical Pharmacist and the Interim Director of the Herston Infectious Diseases Institute (HeIDI) at Royal Brisbane and Women’s Hospital. Jason Roberts is a Clinical Pharmacist with expertise in antimicrobial pharmacokinetics/pharmacodynamics and drug dosing. He has extensive experience in laboratory-based and clinically-focused studies and intervention trials. He has authored >600 publications in peer-reviewed journals and has >$50m in grant funding.
Professor Jason Roberts

Scientific Advisor PK/PD, Clinical Pharmacology, Clinical Research

Professor Holford obtained his medical qualifications (MBChB, MRCP) in the United Kingdom. In 1983 he moved to Auckland, New Zealand to join the University of Auckland in the Dept of Pharmacology & Clinical Pharmacology. Until 1989 he had a part time appointment as a Specialist in Internal Medicine at Auckland Hospital. During this period he was elected a Fellow of the Royal Australasian College of Physicians. He retired from the University of Auckland as Professor Emeritus of Clinical Pharmacology at the end of 2021. His interests are in applying pharmacokinetics and pharmacodynamics to clinical pharmacology and developing tools to aid dose individualization (www.nextdose.org).
Professor Nick Holford

Scientific Advisor Pharmacometrics, Clinical Pharmacology

Our Vision

Our vision is to revolutionize Biopharmaceutical & through Knowledge-Empowered Modeling.

Our Mission

Our mission is to enable biopharmaceutical companies through knowledge-empowered modeling, leveraging proprietary data and AI/ML analytics for a deeper understanding of biological systems. Our services accelerate the discovery and delivery of safe and effective therapies that improve healthcare outcomes worldwide.

Our Values

01

Excellence

Science-Driven Excellence is the cornerstone of our commitment to delivering unparalleled quality and reliability in every facet of our modeling services, ensuring that our clients receive the utmost in scientific rigor and innovation.

02

Innovation

We are relentless innovators, driving progress, and pushing the boundaries of what’s possible. We foster a culture of continuous improvement.

03

Continuous Learning

As a learning organization, we cultivate a culture of continuous growth, investing in the development of our employees to stay at the forefront of advancements.

04

Integrity

Integrity is our ethical foundation and is at the core of our business. We conduct ourselves with honesty and accountability, prioritizing data privacy and security across every level of our organization.

05

Customer-Focus

Working cohesively as one team, we are dedicated to our customers success, delivering tailored solutions with a customer-centric approach.

Explore
Drag